These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 15738295)

  • 41. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature.
    Eriksson C; Gustavsson A; Kronvall T; Tysk C
    J Gastrointestin Liver Dis; 2011 Mar; 20(1):77-80. PubMed ID: 21451802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.
    Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G
    Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    D'Alto M; Romeo E; Argiento P; D'Andrea A; Sarubbi B; Correra A; Scognamiglio G; Papa S; Bossone E; Calabrò R; Vizza CD; Russo MG
    Int J Cardiol; 2013 Apr; 164(3):323-6. PubMed ID: 21802156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.
    Degano B; Yaïci A; Le Pavec J; Savale L; Jaïs X; Camara B; Humbert M; Simonneau G; Sitbon O
    Eur Respir J; 2009 Jan; 33(1):92-8. PubMed ID: 18799506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats.
    Sogni P; Moreau R; Gomola A; Gadano A; Cailmail S; Calmus Y; Clozel M; Lebrec D
    Hepatology; 1998 Sep; 28(3):655-9. PubMed ID: 9731554
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.
    Benza RL; Rayburn BK; Tallaj JA; Coffey CS; Pinderski LJ; Pamoukian SV; Bourge RC
    Chest; 2006 Apr; 129(4):1009-15. PubMed ID: 16608951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
    Ashfaq M; Chinnakotla S; Rogers L; Ausloos K; Saadeh S; Klintmalm GB; Ramsay M; Davis GL
    Am J Transplant; 2007 May; 7(5):1258-64. PubMed ID: 17286619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
    van Loon RL; Hoendermis ES; Duffels MG; Vonk-Noordegraaf A; Mulder BJ; Hillege HL; Berger RM
    Am Heart J; 2007 Oct; 154(4):776-82. PubMed ID: 17893008
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
    Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
    Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Successful management of portopulmonary hypertension with beraprost.
    Kim EJ; Shin MS; Oh KY; Kim MG; Shin KC; Park YM; Kim BR; Chung WJ; Ahn TH; Choi IS; Shin EK
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1503-5. PubMed ID: 21389799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
    Hirono K; Yoshimura N; Taguchi M; Watanabe K; Nakamura T; Ichida F; Miyawaki T
    J Thorac Cardiovasc Surg; 2010 Aug; 140(2):346-51. PubMed ID: 20434177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
    Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
    Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
    Hoeper MM; Kramm T; Wilkens H; Schulze C; Schäfers HJ; Welte T; Mayer E
    Chest; 2005 Oct; 128(4):2363-7. PubMed ID: 16236895
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
    Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.